Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma

This article reviews clinical case of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer and the usage of osimertinib for its treatment. Targeted drugs, EGFR tyrosine kinase inhibitors were approved for the treatment of non-small cell lung cancer more than 15 years...

Full description

Bibliographic Details
Main Authors: Svetlana V. Odintsova, Mariia A. Sviridenko, Antonina O. Cheremnykh, Elena A. Filippova, Magaripa A. Urtenova, Sergei V. Orlov
Format: Article
Language:Russian
Published: IP Habib O.N. 2020-07-01
Series:Современная онкология
Subjects:
Online Access:https://modernonco.orscience.ru/1815-1434/article/viewFile/34962/23379